Asset Manager

Updated:

KreaMedica

KreaMedica is a asset manager based in Montreal; the Altss profile covers its classification, headquarters, registration, AUM band, and key contacts for...

KreaMedica

KreaMedica: The premier biotechnology consulting company and outsourcing partner for all your biotech project needs.

General information

Firm type

Asset Manager

Location

Region

North America

Country

Canada

City

Montreal

Corporate office

7236 Waverly Street Montreal, Quebec, H2R 0C2 CANADA

Additional offices

Oakland, CA · Palo Alto, CA · Seoul, South Korea · Tel Aviv, Israel

Principals

Karl-Rudolf Erlemann

Leadership Team

Vik Pham

Leadership Team

Christina Wizemann

Leadership Team

Francois Duguay

Leadership Team

Dominic Poulin

Leadership Team

Sector focus

Biotech

Frequently asked questions

How does KreaMedica structure its engagements with biotech sponsors?

The firm positions itself as a general contractor rather than a traditional consulting agency. It identifies suitable CRO and CMO vendors, prepares and manages budgets, oversees daily monitoring, and delivers a submission-ready package upon program completion. Clients retain strategic control while KreaMedica absorbs operational and vendor-management accountability.

What therapeutic areas does KreaMedica specialize in?

Its website highlights deep expertise in biologics, inhalation drug delivery, vaccine development, and CNS therapeutics. These areas involve complex pharmacology, unique regulatory pathways, and specialized CRO networks — which aligns with KreaMedica's model of assembling fit-for-purpose vendor teams rather than applying a one-size-fits-all approach.

What is KreaConnect, and how does it supplement KreaMedica's core services?

KreaConnect is an on-demand expert marketplace integrated into KreaMedica's offering. It gives clients rapid access to vetted consultants in regulatory affairs, CMC, pharmacology, toxicology, and clinical strategy. This allows sponsors to fill precise expertise gaps without adding permanent headcount, directly reinforcing the firm's lean virtual-team philosophy.

Who leads KreaMedica, and what is their professional background?

The firm's website identifies a five-person leadership team: Karl-Rudolf Erlemann (Ph.D.), Vik Pham (B.Sc.), Christina Wizemann, Francois Duguay, and Dominic Poulin (M.Sc.). Specific prior roles and career histories are not detailed on the site, and the firm does not assign formal titles beyond Leadership Team membership.

Does KreaMedica invest capital into its biotech clients, or is it purely a service provider?

The website states that KreaMedica has invested in biotech companies at the seed and Series A stages, but it provides no details on fund size, check size, or investment vehicle structure. The firm does not position itself as a dedicated venture investor, and its core disclosed activity remains fee-for-service drug-development outsourcing.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on asset managers?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

More Montreal Asset Manager profiles